Home › Regulus Therapeutics Inc (RGLS) Earns Buy Rating from Analysts at Chardan Capital
 

Keywords :   


Regulus Therapeutics Inc (RGLS) Earns Buy Rating from Analysts at Chardan Capital

2016-04-14 08:07:13| Biotech - Topix.net

The brokerage set a "buy" rating and a $15.00 price target on the biopharmaceutical company's stock. Chardan Capital's target price suggests a potential upside of 91.08% from the company's previous close.

Tags: buy rating capital analysts

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.07Atlantic Tropical Weather Outlook
06.07Tropical Storm Beryl Public Advisory Number 30A
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Eastern North Pacific Tropical Weather Outlook
06.07Tropical Storm Beryl Potential Storm Surge Flooding Map
06.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
06.07Tropical Storm Beryl Forecast Discussion Number 30
06.07Tropical Storm Beryl Graphics
More »